Sisram Medical Ltd, an investment holding company, designs, develops, manufactures, and sells energy-based aesthetic medical, minimally invasive treatment systems, and non-energy based devices and cosmeceuticals in the Asia Pacific, Europe, North America, Latin America, the Middle East, and Africa. It offers products and treatments portfolio, including hair removal, skin rejuvenation, acne and acne scars, body and face contouring, pigmentation and skin resurfacing, fat grafting, dermal facial fillers, skin tissue remodelling injectables, personal care, aesthetic dentistry, trans epidermal delivery, cellulite treatment, stretch marks, vascular and pigmented lesions, hydradermabrasion, blepharoplasty-non surgical eyelid lift, liposuction, feminine health, and sexual rehabilitation. The company manufactures, distributes, and sells medical equipment. It offers its products under the Alma, Soprano, Harmony, Copulla, Foshion, Accent, and LMNT brands. Sisram Medical Ltd was incorporated in 2013 and is headquartered in Caesarea, Israel.

Sisram Medical Ltd

Sisram Medical is a global consumer wellness group that specializes in harnessing natural energy sources for the treatment of aesthetics and medical clinical indications, self-described as deeply rooted in the global medical aesthetics industry for over two decades.

Sisram Medical

Sisram Medical | 1,823 followers on LinkedIn. Sisram Medical Ltd (1696.HK), the first Israeli company listed on the Hong Kong Stock Exchange Main Board, was established in 2013 for the acquisition of Alma, a leading provider of energy-based surgical and medical aesthetics devices, one of the top global leaders in its industry. Sisram Medical is majority held by Fosun Pharma, a leading healthcare group in the people&#39;s republic of China. Sisram is active across over 90 countries worldwide with 9 subsidiaries.

CEO at Sisram Medical & Alma | FOSUN Global Partner

Lior Dayan

Medical Device Quality & Regulatory

Hirshnzon Avi

Chief Operations Officer at Sisram Medical

Ran Ezioni

Deputy Regional CEO, North America, Sisram Medical Ltd

Annie Belsham

“In the rapidly evolving medical aesthetic industry, Sisram has achieved an all-time high in new orders, reflecting strong customer confidence in Alma’s core platforms. This milestone, driven by the rapid and better-than-expected market adoption of Alma’s recent launches, showcases our commitment to delivering high-value offerings to our partners and increasing patient lifetime value to support clinic growth,” says Sisram and Alma CEO, Lior Dayan . Sisram Medical announces First-Half 2024 performance>> https://bit.ly/4eaBSEy

Sisram Medical announces First-Half 2024 performance, with the EBD segment maintaining steady growth and direct sales reaching a new all-time high. #medicalaesthetics #wellness #ecosystem #sisrammedical

Sisram Medical announces 2023 annual revenue results of US$359.3M, marking all-time record high for the direct sales portion #medicalaesthetics #wellness #ecosystem #sisrammedical

1696

COM:SISRAM-MEDICAL

Sisram Medical

Last Close

3.17

25/11 07:23

Market Cap

1.55B

Beta: -

Volume Today

167.20K

Avg: -

Financials Not Available